We validated the association between IFNA17 levels and tumor grade and confirmed that IFNA17 was enhanced in primary and metastatic prostate cancer samples compared to those in normal prostate (Fig. 4G) and in prostate cancer samples with high Gleason scores (Fig. 4H). The gene discussed is IFNA17; the disease is metastatic prostate carcinoma.